SecBot SecBot
6-K ·Filed Aug 13, 2026

ASND

Ascendis Pharma A/S
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0001612042-26-000016
Notable filing: 6-K
Actionable Insight ▲ Bullish

The strong Q2 beat and balance sheet cleanup (convertible note redemption, deferred tax asset recognition) mark a fundamental inflection point. Traders should watch for the EU MAA decision on YUVIWEL in Q4 2026 as a key catalyst. The COACH combination therapy data supports a potential expansion of the achondroplasia market opportunity. Monitor SG&A trajectory for margin expansion as the commercial infrastructure scales.

DirectionBullish
Confidencehigh
Horizonweeks

Drugs in focus

ASND drug pipeline →

lonapegsomatropin

● Neutral Named in this 6-K
Impact
Phase
Approved
Time to market
Already approved and marketed (FDA approval August 2021)
Next catalyst
None dated

What to watchSkytrofa is a steady commercial contributor but not the primary value driver for ASND anymore, YORVIPATH's rapid growth and the YUVIWEL launch are the main catalysts. Watch for any FDA filing for adult GHD indication (completed Phase 3 data in hand) and quarterly Skytrofa sales trajectory. The stock's next major binary catalyst is the EU MAA decision for YUVIWEL expected in Q4 2026.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$246.23
T+0 close · Aug 13, 2026 · via day close
Latest settled
+4.30%
T+60 · $256.82
Vs SPY
+9.78%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 13 $246.23entry
  2. T+1 · 3mo ago +0.92%α +1.12% · $248.50
  3. T+5 · 3mo ago +3.48%α +5.45% · $254.81
  4. T+20 · 2mo ago +7.02%α +8.77% · $263.52
  5. T+60 · 10d ago +4.30%α +9.78% · $256.82
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ascendis Pharma reported a transformative Q2 2026 with revenue surging to EUR 339.3M (up 115% YoY) driven by YORVIPATH growth and the YUVIWEL launch, generating a net profit of EUR 207.0M vs a loss of EUR 38.9M a year ago. The company also recognized a EUR 679.6M deferred tax asset and sold a Priority Review Voucher for $187.5M, while fully redeeming its $575M convertible notes via equity conversion, strengthening the balance sheet. The strong commercial execution and pipeline progress (COACH combination therapy data, EU MAA decision for YUVIWEL expected Q4 2026) support a bullish outlook, though elevated SG&A costs from commercial expansion and ongoing IP litigation with BioMarin are risks to monitor.

Key Facts

  • Q2 2026 revenue of EUR 339.3M, up 115% YoY from EUR 158.0M
  • YORVIPATH revenue of EUR 252.1M in Q2 2026, up 145% YoY from EUR 103.0M
  • YUVIWEL (navepegritide) launched in the U.S. in Q2 2026, contributing EUR 7.6M in revenue
  • Net profit of EUR 207.0M in Q2 2026 vs net loss of EUR 38.9M in Q2 2025
  • Recognized EUR 679.6M deferred tax asset in H1 2026, reflecting improved profitability outlook
  • Sold Rare Pediatric Disease Priority Review Voucher for $187.5M, netting EUR 158.1M in other operating income
  • Fully redeemed $575M 2.25% convertible notes due 2028 via equity conversion on May 6, 2026, eliminating debt and derivative liabilities
  • Cash and cash equivalents of EUR 812.3M as of June 30, 2026, up from EUR 616.0M at year-end 2025
  • COACH combination therapy (TransCon CNP + TransCon hGH) showed sustained growth at Week 78, with 100% retention
  • EU MAA decision for YUVIWEL (navepegritide) expected in Q4 2026

Financial Impact

Revenue more than doubled YoY to EUR 339.3M (Q2) and EUR 585.9M (H1). Net income swung from a loss of EUR 38.9M to a profit of EUR 207.0M in Q2. The balance sheet was strengthened by EUR 719.5M in equity from convertible note conversion and a EUR 699.3M deferred tax asset.

revenuenet incomecash and cash equivalentsdebtequitydeferred tax assets

Risk Factors

  • Ongoing IP litigation with BioMarin regarding TransCon CNP (YUVIWEL) in the U.S. (ITC) and other jurisdictions could create overhang
  • Elevated SG&A expenses (EUR 318.6M in H1 2026) from commercial expansion may pressure margins if revenue growth decelerates
  • EU MAA decision for YUVIWEL in Q4 2026 is binary and could impact ex-U.S. revenue expectations
  • Tariff uncertainty on pharmaceutical imports could impact supply chain costs
  • Foreign exchange risk from USD-denominated revenue and EUR reporting currency

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
96% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001612042-26-000016
Document: 0001612042-26-000016-index-headers.html0001612042-26-000016
Document: 0001612042-26-000016-index.html0001612042-26-000016
Document: 0001612042-26-000016.txt0001612042-26-000016

Track record

41 reports on ASND

Performance horizon

13 of 18 bullish or bearish reports moved the stock their way by T+60. Best: +26.62% at T+20 after the Jun 2, 2026 report. 23 of 26 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $271.96 Now $271.63 −0.12% settles Feb 12
  2. Nov 12, 20263d ago 6-K Neutral 2/10 Entry $267.07 Now $271.63 +1.71% settles Feb 11
  3. Nov 12, 20264d ago 6-K Bullish 6/10 Entry $267.07 Now $271.63 +1.71% settles Feb 10
  4. Nov 12, 20264d ago Press Release Neutral 5/10 Entry $267.07 Now $271.63 +1.71% settles Feb 10
  5. Nov 6, 20269d ago 6-K Bullish 6/10 Entry $259.85 Now $271.63 +4.53% settles Feb 5
  6. Nov 6, 202610d ago Press Release Bullish 6/10 Entry $256.82 Now $271.63 +5.77% settles Feb 4
  7. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $253.45 Now $271.63 +7.17% settles Feb 3
  8. Nov 2, 202613d ago Institutional Cluster Bullish 4/10 Entry $250.17 Now $271.63 +8.58% settles Feb 1
  9. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $245.85 Now $271.63 +10.49% settles Jan 25
  10. Oct 16, 20264w ago 6-K Bullish 7/10 Entry $225.25 Now $271.63 +20.59% settles Jan 13
Showing 10 of 41

US Market Status

Market Open · Closes in 14m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 13, 2026